$HTLD
HEARTLAND EXPRESS INC

2023 Q3 Form 10-Q Financial Statement

#000079923323000037 Filed on August 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $295.0M $306.2M
YoY Change 7.67% 63.03%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $235.2M $233.3M
YoY Change 19.29% 82.34%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $51.10M $48.34M
YoY Change 46.89% 98.84%
% of Gross Profit
Operating Expenses $303.6M $298.0M
YoY Change 23.38% 81.16%
Operating Profit -$7.440M $16.23M
YoY Change -121.42% -84.55%
Interest Expense $6.067M -$5.519M
YoY Change -435.56% -3271.84%
% of Operating Profit -34.0%
Other Income/Expense, Net
YoY Change
Pretax Income -$13.23M $10.71M
YoY Change -140.17% -89.81%
Income Tax -$2.528M $2.940M
% Of Pretax Income 27.45%
Net Earnings -$10.70M $7.771M
YoY Change -143.84% -89.9%
Net Earnings / Revenue -3.63% 2.54%
Basic Earnings Per Share -$0.14 $0.10
Diluted Earnings Per Share -$0.14 $0.10
COMMON SHARES
Basic Shares Outstanding 79.03M shares 78.99M shares
Diluted Shares Outstanding 79.10M shares 79.08M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.10M $46.25M
YoY Change -68.99% -73.09%
Cash & Equivalents $20.10M $46.25M
Short-Term Investments
Other Short-Term Assets $20.74M $30.12M
YoY Change -45.83% 50.92%
Inventory
Prepaid Expenses
Receivables $113.9M $114.5M
Other Receivables $15.40M $7.927M
Total Short-Term Assets $182.1M $198.8M
YoY Change -31.59% -32.88%
LONG-TERM ASSETS
Property, Plant & Equipment $926.1M $941.6M
YoY Change -6.68% 84.34%
Goodwill $322.6M $320.7M
YoY Change 1.83% 53.58%
Intangibles $99.80M $101.1M
YoY Change -3.39% 105.36%
Long-Term Investments
YoY Change
Other Assets $31.98M $34.52M
YoY Change 39.46% 77.44%
Total Long-Term Assets $1.393B $1.398B
YoY Change -2.92% 71.08%
TOTAL ASSETS
Total Short-Term Assets $182.1M $198.8M
Total Long-Term Assets $1.393B $1.398B
Total Assets $1.576B $1.597B
YoY Change -7.41% 43.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $60.30M $61.05M
YoY Change 1.43% 111.94%
Accrued Expenses $72.70M $74.30M
YoY Change -8.53% -0.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $9.131M $12.60M
YoY Change -48.26% 446.74%
Total Short-Term Liabilities $142.1M $147.9M
YoY Change -11.08% 17.09%
LONG-TERM LIABILITIES
Long-Term Debt $334.8M $336.2M
YoY Change -25.16% 3798.61%
Other Long-Term Liabilities $42.20M $45.19M
YoY Change -22.55% -19.11%
Total Long-Term Liabilities $572.3M $381.4M
YoY Change 14.03% 125.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $142.1M $147.9M
Total Long-Term Liabilities $572.3M $381.4M
Total Liabilities $714.4M $723.7M
YoY Change -17.0% 145.08%
SHAREHOLDERS EQUITY
Retained Earnings $1.057B $1.069B
YoY Change 1.82% 5.32%
Common Stock $5.168M $4.805M
YoY Change -0.84% -5.75%
Preferred Stock
YoY Change
Treasury Stock (at cost) $200.6M $200.7M
YoY Change -0.71% -0.67%
Treasury Stock Shares
Shareholders Equity $861.1M $872.9M
YoY Change
Total Liabilities & Shareholders Equity $1.576B $1.597B
YoY Change -7.41% 43.43%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$10.70M $7.771M
YoY Change -143.84% -89.9%
Depreciation, Depletion And Amortization $51.10M $48.34M
YoY Change 46.89% 98.84%
Cash From Operating Activities $27.20M $30.81M
YoY Change -49.67% 47.33%
INVESTING ACTIVITIES
Capital Expenditures $68.90M $65.87M
YoY Change -267.01% -330.84%
Acquisitions
YoY Change
Other Investing Activities $20.70M $44.91M
YoY Change -103.85% -862.98%
Cash From Investing Activities -$48.00M -$20.96M
YoY Change -91.7% -39.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -6.800M -19.14M
YoY Change -101.63% 604.56%
NET CHANGE
Cash From Operating Activities 27.20M 30.81M
Cash From Investing Activities -48.00M -20.96M
Cash From Financing Activities -6.800M -19.14M
Net Change In Cash -27.60M -9.288M
YoY Change -74.19% -42.74%
FREE CASH FLOW
Cash From Operating Activities $27.20M $30.81M
Capital Expenditures $68.90M $65.87M
Free Cash Flow -$41.70M -$35.05M
YoY Change -143.76% -170.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.02
CY2022Q2 htld Restricted Cash And Investments Current Total
RestrictedCashAndInvestmentsCurrentTotal
900000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
13900000 usd
CY2023Q2 htld Restricted Stock Shares Remaining Available
RestrictedStockSharesRemainingAvailable
486531 shares
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0 usd
CY2023Q2 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
300000 usd
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.274 rate
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.266 rate
htld Net Income2
NetIncome2
20383000 usd
htld Net Income2
NetIncome2
93681000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
96806000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
47620000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
13440000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
12709000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
393000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
343000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
539000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
14809000 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
85970000 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-25348000 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
10600000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-6193000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
778000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-19086000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
8521000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-5071000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
18400000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
97256000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
58508000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
73838000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
129820000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
108017000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50563000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
-122049000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-419000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
9000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33760000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42801000 usd
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
1581000 usd
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
1579000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
155000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
66000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
64773000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1113000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-66509000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2758000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3013000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
12949000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61465000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
186716000 usd
us-gaap Interest Paid Net
InterestPaidNet
159000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
18683000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1033000 usd
htld Soldrevenueequipmentinothercurrentassets
Soldrevenueequipmentinothercurrentassets
494000 usd
htld Soldrevenueequipmentinothercurrentassets
Soldrevenueequipmentinothercurrentassets
3084000 usd
htld Common Stock Dividends Declared In Accounts Payable
CommonStockDividendsDeclaredInAccountsPayable
1580000 usd
htld Common Stock Dividends Declared In Accounts Payable
CommonStockDividendsDeclaredInAccountsPayable
1579000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4653000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46250000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
171879000 usd
CY2023Q2 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
741000 usd
CY2022Q2 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
897000 usd
CY2023Q2 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
14474000 usd
CY2022Q2 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
13940000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61465000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
186716000 usd
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
us-gaap Use Of Estimates
UseOfEstimates
Use of EstimatesThe preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segments
CY2023Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2400000 usd
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2600000 usd
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023Q2 us-gaap Revenues
Revenues
306200000 usd
CY2022Q2 us-gaap Revenues
Revenues
187800000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
24700000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4300000 usd
us-gaap Revenues
Revenues
637100000 usd
us-gaap Revenues
Revenues
339100000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
49300000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7500000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
15200000 usd
CY2023Q2 htld Restricted Cash And Investments Current Total
RestrictedCashAndInvestmentsCurrentTotal
700000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
14500000 usd
htld Amortization Period Of Tires
AmortizationPeriodOfTires
two years
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
htld Increase Decrease Of Restricted Cash And Investments
IncreaseDecreaseOfRestrictedCashAndInvestments
500000 usd
CY2022 htld Increase Decrease Of Restricted Cash And Investments
IncreaseDecreaseOfRestrictedCashAndInvestments
1600000 usd
us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
0 usd
CY2023Q2 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
0 usd
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023Q2 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
101100000 usd
CY2023Q2 us-gaap Indefinite Lived Trade Names
IndefiniteLivedTradeNames
31600000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000 usd
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2600000 usd
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
94575000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
25099000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
69476000 usd
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023Q2 htld Net Income Loss Eps
NetIncomeLossEPS
7771000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78999000 shares
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
CY2023Q2 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0 usd
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
82000 shares
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
7771000 usd
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79081000 shares
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2022Q2 htld Net Income Loss Eps
NetIncomeLossEPS
76906000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78934000 shares
CY2022Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
1600000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.97
CY2022Q2 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0 usd
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
25000 shares
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
76906000 usd
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78959000 shares
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.97
htld Net Income Loss Eps
NetIncomeLossEPS
20383000 usd
htld Net Income Loss Eps
NetIncomeLossEPS
20383000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78993000 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0 usd
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
59000 shares
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
20383000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79052000 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.26
htld Net Income Loss Eps
NetIncomeLossEPS
93681000 usd
htld Net Income Loss Eps
NetIncomeLossEPS
93681000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78931000 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.19
us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0 usd
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
25000 shares
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
93681000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78956000 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.19
CY2023Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6600000 shares
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
0 shares
CY2022Q2 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
0 shares
CY2023Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
1600000 usd
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
3200000 usd
CY2011Q3 htld Restricted Stock Shares Authorized
RestrictedStockSharesAuthorized
900000 shares
CY2021Q2 htld Restricted Stock Shares Authorized
RestrictedStockSharesAuthorized
600000 shares
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
200000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
400000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
100000 usd
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1300000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y9M18D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
33100 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
16.02
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
93300 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.82
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
31400 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
14.86
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
95000.0 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
15.23
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
27000.0 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
17.37
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
3000.0 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.79
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
5000.0 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
16.60
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
25000.0 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
17.21
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
40100 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
16.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
93300 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.82
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
38400 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
15.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
95000.0 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
15.23
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
14000.0 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
19.70
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
28000.0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
17000.0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
15.83
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
25000.0 shares
CY2023Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
8762000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
17.21
CY2022Q3 htld Unsecured Credit Facility
UnsecuredCreditFacility
550000000 usd
CY2022Q3 htld Revolving Facility
RevolvingFacility
100000000 usd
CY2022Q3 htld Term Facility
TermFacility
450000000 usd
CY2022Q3 htld Revolving Facility
RevolvingFacility
100000000 usd
CY2022Q3 htld Available Issuance Of Line Of Credit
AvailableIssuanceOfLineOfCredit
50000000 usd
CY2022Q3 htld Swingline Facility
SwinglineFacility
20000000 usd
CY2022Q3 htld Uncommitted Accordion Feature
UncommittedAccordionFeature
275000000 usd
htld Max Annual Dividend
MaxAnnualDividend
10000000 usd
htld Debt Instrument Covenant Distributions Max Leverage Ratio
DebtInstrumentCovenantDistributionsMaxLeverageRatio
2.5
htld Debt Instrument Covenant Maximum Net Leverage Ratio
DebtInstrumentCovenantMaximumNetLeverageRatio
2.75
htld Debt Instrument Covenant Minimum Interest Coverage Ratio
DebtInstrumentCovenantMinimumInterestCoverageRatio
3
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
htld Term Sofr One Month Spread
TermSOFROneMonthSpread
0.011 rate
htld Applicable Margin Base
ApplicableMarginBase
0.0100 rate
CY2023Q2 htld Outstanding Debt On Term Facility
OutstandingDebtOnTermFacility
315000000 usd
CY2023Q2 htld Outstanding Debt On Revolving Facility
OutstandingDebtOnRevolvingFacility
0 usd
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
12000000 usd
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023Q2 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
88000000 usd
CY2023Q2 htld Weighted Average Interest Rate Credit Facility
WeightedAverageInterestRateCreditFacility
0.066 rate
CY2023Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
1700000 usd
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2022Q2 htld Business Combination Long Term Debt
BusinessCombinationLongTermDebt
-46800000 usd
CY2023Q2 htld Business Combination Long Term Debt
BusinessCombinationLongTermDebt
-35500000 usd
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023Q2 htld Debt
Debt
8700000 usd
CY2023Q2 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.044 rate
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023Q2 htld Finance Lease Obligations
FinanceLeaseObligations
26800000 usd
CY2023Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.039 rate
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M18D
CY2023Q2 htld Right Of Use Asset Associated With The Leased Terminal Facility
RightOfUseAssetAssociatedWithTheLeasedTerminalFacility
2100000 usd
CY2023Q2 htld Right Of Use Operating Lease Assets
RightOfUseOperatingLeaseAssets
12400000 usd
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.038 rate
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M24D
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5673000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6186000 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
8231000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3003000 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
7511000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
151000 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
3901000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
0 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
0 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15013000 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
28405000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
531000 usd
CY2023Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
1587000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
14482000 usd
CY2023Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
26818000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9436000 usd
CY2023Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
10680000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5046000 usd
CY2023Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
16138000 usd
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0 usd
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5500000 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5700000 usd
CY2023Q2 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
4400000 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
4500000 usd
CY2023Q2 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
300000 usd
CY2022Q2 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
-1300000 usd
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
200000 usd
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
-1100000 usd
CY2023Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
700000 usd
CY2023Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
700000 usd
CY2023Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
-100000 usd
CY2022Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
-100000 usd
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
-100000 usd
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
-200000 usd
us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
176000 usd
us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
391000 usd
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5529000 usd
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023Q2 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
55700000 usd
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30

Files In Submission

Name View Source Status
0000799233-23-000037-index-headers.html Edgar Link pending
0000799233-23-000037-index.html Edgar Link pending
0000799233-23-000037.txt Edgar Link pending
0000799233-23-000037-xbrl.zip Edgar Link pending
exhibit3112023q2.htm Edgar Link pending
exhibit3122023q2.htm Edgar Link pending
exhibit3212023q2.htm Edgar Link pending
exhibit3222023q2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
htld-20230630.htm Edgar Link pending
htld-20230630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
htld-20230630_cal.xml Edgar Link unprocessable
htld-20230630_def.xml Edgar Link unprocessable
htld-20230630_lab.xml Edgar Link unprocessable
htld-20230630_pre.xml Edgar Link unprocessable
htld-20230630_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable